UTHR – United Therapeutics Corporation
Float Short %
3.59
Margin Of Safety %
18
Put/Call OI Ratio
1.02
EPS Next Q Diff
0.01
EPS Last/This Y
0.15
EPS This/Next Y
1.19
Price
312.2
Target Price
386
Analyst Recom
1.71
Performance Q
1.14
Relative Volume
0.85
Beta
0.61
Ticker: UTHR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | UTHR | 304.73 | 1.54 | 0.81 | 17550 |
| 2025-07-28 | UTHR | 298.09 | 1.54 | 1.05 | 17797 |
| 2025-07-29 | UTHR | 297.16 | 1.58 | 0.44 | 18613 |
| 2025-07-30 | UTHR | 281.81 | 1.55 | 15.64 | 18882 |
| 2025-07-31 | UTHR | 274.72 | 2.14 | 1.78 | 22789 |
| 2025-08-01 | UTHR | 294.19 | 2.10 | 3.82 | 23385 |
| 2025-08-04 | UTHR | 292.71 | 2.15 | 1.20 | 23465 |
| 2025-08-05 | UTHR | 304.88 | 0.97 | 0.03 | 32659 |
| 2025-08-06 | UTHR | 302.41 | 0.77 | 0.77 | 37331 |
| 2025-08-07 | UTHR | 299.48 | 0.77 | 0.88 | 37588 |
| 2025-08-08 | UTHR | 301.87 | 0.79 | 0.49 | 41703 |
| 2025-08-11 | UTHR | 300.43 | 0.79 | 0.33 | 41748 |
| 2025-08-12 | UTHR | 301.5 | 0.78 | 1.11 | 42002 |
| 2025-08-13 | UTHR | 309.83 | 0.81 | 1.30 | 46224 |
| 2025-08-14 | UTHR | 311.06 | 0.82 | 0.64 | 46478 |
| 2025-08-15 | UTHR | 313.26 | 0.81 | 3.55 | 47280 |
| 2025-08-18 | UTHR | 313.35 | 1.03 | 3.33 | 39475 |
| 2025-08-19 | UTHR | 313.33 | 1.03 | 1.98 | 39687 |
| 2025-08-20 | UTHR | 306.35 | 1.04 | 0.51 | 39904 |
| 2025-08-21 | UTHR | 310.62 | 1.01 | 0.17 | 40454 |
| 2025-08-22 | UTHR | 312.53 | 1.02 | 0.94 | 40490 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | UTHR | 304.50 | 24.8 | 80.7 | 27.26 |
| 2025-07-28 | UTHR | 298.42 | 24.8 | 50.4 | 27.26 |
| 2025-07-29 | UTHR | 297.56 | 24.8 | 90.0 | 27.26 |
| 2025-07-30 | UTHR | 281.95 | 24.8 | -21.6 | 27.26 |
| 2025-07-31 | UTHR | 274.70 | 24.8 | 36.4 | 27.26 |
| 2025-08-01 | UTHR | 294.28 | 9.7 | 206.6 | 27.04 |
| 2025-08-04 | UTHR | 292.65 | 9.9 | 32.5 | 26.63 |
| 2025-08-05 | UTHR | 304.81 | 9.9 | 137.3 | 26.63 |
| 2025-08-06 | UTHR | 302.63 | 9.9 | 29.8 | 26.96 |
| 2025-08-07 | UTHR | 299.42 | 9.9 | 23.7 | 26.96 |
| 2025-08-08 | UTHR | 301.50 | 9.9 | 60.7 | 26.96 |
| 2025-08-11 | UTHR | 300.49 | 9.9 | 38.0 | 26.96 |
| 2025-08-12 | UTHR | 301.21 | 9.9 | 51.1 | 26.96 |
| 2025-08-13 | UTHR | 309.72 | 9.9 | 106.1 | 26.96 |
| 2025-08-14 | UTHR | 312.10 | 9.9 | 62.2 | 26.96 |
| 2025-08-15 | UTHR | 313.09 | 9.9 | 52.6 | 26.95 |
| 2025-08-18 | UTHR | 314.29 | 9.9 | 53.4 | 26.95 |
| 2025-08-19 | UTHR | 313.22 | 9.9 | 39.3 | 26.95 |
| 2025-08-20 | UTHR | 306.41 | 9.9 | -1.8 | 26.95 |
| 2025-08-21 | UTHR | 310.67 | 10.2 | 75.3 | 26.59 |
| 2025-08-22 | UTHR | 312.20 | 10.2 | 56.2 | 26.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | UTHR | -15.90 | 1.41 | 3.64 |
| 2025-07-28 | UTHR | -16.58 | -0.26 | 3.64 |
| 2025-07-29 | UTHR | -15.96 | -0.26 | 3.64 |
| 2025-07-30 | UTHR | -15.96 | -0.26 | 3.64 |
| 2025-07-31 | UTHR | -15.91 | -0.26 | 3.64 |
| 2025-08-01 | UTHR | -15.91 | -0.26 | 3.64 |
| 2025-08-04 | UTHR | -15.87 | -0.64 | 3.63 |
| 2025-08-05 | UTHR | -15.25 | -0.64 | 3.63 |
| 2025-08-06 | UTHR | -15.25 | -0.64 | 3.63 |
| 2025-08-07 | UTHR | -15.25 | -0.64 | 3.63 |
| 2025-08-08 | UTHR | -15.93 | -0.64 | 3.63 |
| 2025-08-11 | UTHR | -15.93 | -0.70 | 3.63 |
| 2025-08-12 | UTHR | -15.31 | -0.70 | 3.56 |
| 2025-08-13 | UTHR | -15.31 | -0.70 | 3.56 |
| 2025-08-14 | UTHR | -15.31 | -0.70 | 3.56 |
| 2025-08-15 | UTHR | -15.31 | -0.70 | 3.56 |
| 2025-08-18 | UTHR | -15.31 | -2.26 | 3.56 |
| 2025-08-19 | UTHR | -15.31 | -2.26 | 3.59 |
| 2025-08-20 | UTHR | -11.75 | -2.26 | 3.59 |
| 2025-08-21 | UTHR | -11.75 | -2.26 | 3.59 |
| 2025-08-22 | UTHR | -12.32 | -2.26 | 3.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.41
Avg. EPS Est. Current Quarter
7.07
Avg. EPS Est. Next Quarter
6.42
Insider Transactions
-12.32
Institutional Transactions
-2.26
Beta
0.61
Average Sales Estimate Current Quarter
820
Average Sales Estimate Next Quarter
802
Fair Value
367.15
Quality Score
100
Growth Score
98
Sentiment Score
51
Actual DrawDown %
25.3
Max Drawdown 5-Year %
-33
Target Price
386
P/E
12.19
Forward P/E
10.67
PEG
2.37
P/S
4.59
P/B
1.97
P/Free Cash Flow
13.22
EPS
25.61
Average EPS Est. Cur. Y
26.59
EPS Next Y. (Est.)
27.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.36
Relative Volume
0.85
Return on Equity vs Sector %
-7.4
Return on Equity vs Industry %
9.5
EPS 1 7Days Diff
-0.4
EPS 1 30Days Diff
-0.77
EBIT Estimation
56.2
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading